PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial by the German Hodgkin Study Group
Jacob, AS; Fuchs, M; Kaul, H; Kobe, C; Pabst, T; Greil, R; Eichenauer, D; Topp, M; Just, M; Hertenstein, B; Schaub, V; Vogelhuber, M; Zijlstra, JM; Pluetschow, A; Baues, C; Rosenwald, A; Dietlein, M; Borchmann, P; Engert, A ONCOL RES TREAT. 2022; 45(SUPPL 3): 168-168.
SEQUOIA: Results of a Phase 3 Randomised Study of Zanubrutinib versus Bendamustine plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
Munir, T; Giannopoulos, K; Jurczak, W; Simkovic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, H; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Kahl, BS; Ghia, P; Li, JY; Tian, T; Zhou, L; Marimpietri, C; Paik, JC; Cohen, A; Huang, J; Brown, JR; Robak, T; Tam, CS BRIT J HAEMATOL. 2022; 197: 95-96.
Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Miguel, J; Burgues, B; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Abrisqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, C; Salles, G; Collins, G BRIT J HAEMATOL. 2022; 197: 14-16.
Sequoia: Results of a randomized phase iii trial of zanubrutinib versus bendamustine plus rituximab (br) in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Greil, R; Robak, T; Giannopoulos, K; Jurczak, W; Simkovic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, H; Ciepluch, H; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Brown, JR; Kahl, BS; Ghia, P; Li, J; Tian, T; Zhou, L; Marimpietri, C; Paik, JC; Cohen, A; Hillmen, P; Tam, CS ONCOL RES TREAT. 2022; 45(SUPPL 2): 117-118.
The influence of pancreatic regression characteristics on outcome of neoadjuvant treated pancreatic cancer in two Austrian university centres
Neumayer, B; Neureiter, D; Klieser, E; Huemer, F; Weiss, L; Greil, R; Djanani, A; Oberhuber, G; Schlick, K Virchows Archiv. 2022; 481(Supplement 1):S135-S135.-34th European Congress of Pathology; 03.-07.09.2022; Basel.
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
Harbeck, N; Wrobel, D; Zaiss, M; Guth, D; Distelrath, A; Terhaag, J; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Luftner, D ANN ONCOL. 2022; 33: S157-S157.
Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
Gampenrieder, SP; Dezentje, V; Lambertini, M; de Nonneville, A; Marhold, M; Le Du, F; Serrano, CS; Costa, DA; Blondeaux, E; Del Mastro, L; Bertucci, F; Goncalves, A; Bartsch, R; Deleuze, A; Salgado, AC; Vitorino, M; Tinchon, C; Pecen, L; Rinnerthaler, G; Greil, R ANN ONCOL. 2022; 33: S208-S208.
Updated Results of Tucatinib versus Placebo in Combination with Trastuzumab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB)
Greil, R; Lin, UN; Murthy, KR; Abramson, V; Anders, C; Bachelot, T; Bedard, LP; Borges, V; Cameron, D; Carey, L; Chien, JA; Curigliano, G; DiGiovanna, PM; Gelmon, K; Hortobagyi, G; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Oliveira, M; Paplomata, E; Pegram, M; Slamon, D; Zelnak, A; Ramos, J; Feng, W; Winer, E GEBURTSH FRAUENHEILK. 2022; 82(4): E4-E5.
REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R ANN ONCOL. 2022; 33: S217-S217.
Pola-R-ICE: Results of the safety run-in phase of a phase III study comparing polatuzumab vedotin in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) with R-ICE alone in patients with refractory or relapsed diffuse large B-cell lymphoma
Laube, A; Fuhrmann, S; Van Heteren, P; Ziepert, M; Altmann, B; Davies, A; Greil, R; Garcia-Sancho, AM; Pellon, SGD; Schnetzke, U; De la Cruz Vicente, F; Hanel, M; Hess, G; Kohler, C; Masius, H; Glass, B ONCOL RES TREAT. 2022; 45(SUPPL 2): 83-84.
